Structure via PubChem · Public domain (PubChem)
posaconazole
Sign in to savePosaconazole, sold under the brand name Noxafil among others, is a triazole antifungal medication.
Chemical data
- Formula
- C37H42F2N8O4
- Molecular weight
- 700.8 g/mol
- IUPAC name
- 4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one
- SMILES
- CC[C@@H]([C@H](C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5C[C@](OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F
- InChIKey
- RAGOYPUPXAKGKH-XAKZXMRKSA-N
- XLogP
- 4.6
- Polar surface area
- 112 Ų
- H-bond donors
- 1
- H-bond acceptors
- 11
- Formal charge
- 0
via PubChem
Research
4,218 papers- Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial.Lancet (London, England) · 2021
- Posaconazole.Drugs · 2005
- Posaconazole.Drugs of today (Barcelona, Spain : 1998) · 2005
- Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.The New England journal of medicine · 2007
- Posaconazole in immunocompromised pediatric patients.Expert review of anti-infective therapy · 2018
via PubMed
~2 min read
Encyclopedic overview
6 sectionsContents
- Medical uses
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- References
- External links
Posaconazole, sold under the brand name Noxafil among others, is a triazole antifungal medication.
It was approved for medical use in the European Union in October 2005, and in the United States in September 2006. It is available as a generic medication.
Excerpted from Wikipedia’s “posaconazole” article, available under the CC BY-SA 4.0 licence.